Email this article Adjuvant androgenic blockade after teleradiotherapy for prostate cancer: long-term results of phase III rtog 85-31 study
- Authors: Pilepich M.V.1, K.W.2, Lawton C.A.3, Krisch R.E.4, Wolkov H.B.5, Movsas B.6, Hug E.B.7, Asbell S.O.8, Grignon D.9
-
Affiliations:
- California University, Los Angeles, School of Medicine, Los Angeles, CA
- Group of Radiation Therapy in Oncology, Philadelphia, PA
- Wisconsin Medical College, Milluoki, WI
- University of Pennsylvania State, Philadelphia, PA
- Association of Radiology of Sacramento, Sacramento, CA
- Fox Chase Cancer Center, Philadelphia, PA
- Hitchcock Dartmouth Medical Center, Lebanon, NH
- Albert Einstein Medical Center, Philadelphia, PA
- Whane State University, Detroit, MI
- Issue: Vol 3, No 1 (2007)
- Pages: 59-65
- Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCER
- Published: 30.03.2007
- URL: https://oncourology.abvpress.ru/oncur/article/view/1089
- DOI: https://doi.org/10.17650/1726-9776-2007-3-1-59-65
- ID: 1089
Cite item
Full Text
Abstract
The RTOG 85-31 study has indicated that adjuvant hormonotherapy is particularly effective in prostate cancer (PC) patients with a high Glisson score. Long-term adjuvant hormonotherapy is not warranted in patients with a total Glisson score of 2-6. Exception is patients with disseminated locally advanced tumors, in whom neoadjuvant androgenic suppression (RTOG 86-10 protocol) considerably improves the results of treatment. Long-term adjuvant hormonotherapy may be the method of choice in treating PC patients with a poor prognosis.
About the authors
Miljenko V. Pilepich
California University, Los Angeles, School of Medicine, Los Angeles, CA
Author for correspondence.
M.D. United States
Kathryn Winter
Group of Radiation Therapy in Oncology, Philadelphia, PAM.S. United States
Colleen A. Lawton
Wisconsin Medical College, Milluoki, WIM.D. United States
Robert E. Krisch
University of Pennsylvania State, Philadelphia, PAM.D. United States
Harvey B. Wolkov
Association of Radiology of Sacramento, Sacramento, CAM.D. United States
Benjamin Movsas
Fox Chase Cancer Center, Philadelphia, PAM.D. United States
Eugen B. Hug
Hitchcock Dartmouth Medical Center, Lebanon, NHM.D. United States
Sucha O. Asbell
Albert Einstein Medical Center, Philadelphia, PAM.D. United States
David Grignon
Whane State University, Detroit, MIM.D. United States
References
Supplementary files
